Capricor Therapeutics’ (CAPR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note released on Friday morning,Benzinga reports. The firm currently has a $77.00 price target on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating and set […]
HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note released on Friday morning,Benzinga reports. The firm currently has a $77.00 price target on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating and set […]
